Literature DB >> 27809955

Live Attenuated Human Salmonella Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity.

James E Galen1, Amanda D Buskirk2, Sharon M Tennant2, Marcela F Pasetti2.   

Abstract

Salmonellosis, caused by members of the genus Salmonella, is responsible for considerable global morbidity and mortality in both animals and humans. In this review, we will discuss the pathogenesis of Salmonella enterica serovar Typhi and Salmonella enterica serovar Typhimurium, focusing on human Salmonella infections. We will trace the path of Salmonella through the body, including host entry sites, tissues and organs affected, and mechanisms involved in both pathogenesis and stimulation of host immunity. Careful consideration of the natural progression of disease provides an important context in which attenuated live oral vaccines can be rationally designed and developed. With this in mind, we will describe a series of attenuated live oral vaccines that have been successfully tested in clinical trials and demonstrated to be both safe and highly immunogenic. The attenuation strategies summarized in this review offer important insights into further development of attenuated vaccines against other Salmonella for which live oral candidates are currently unavailable.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27809955      PMCID: PMC5119766          DOI: 10.1128/ecosalplus.ESP-0010-2016

Source DB:  PubMed          Journal:  EcoSal Plus        ISSN: 2324-6200


  110 in total

1.  Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine.

Authors:  M M Levine; C Ferreccio; P Abrego; O S Martin; E Ortiz; S Cryz
Journal:  Vaccine       Date:  1999-10-01       Impact factor: 3.641

2.  Dissemination of invasive Salmonella via bacterial-induced extrusion of mucosal epithelia.

Authors:  Leigh A Knodler; Bruce A Vallance; Jean Celli; Seth Winfree; Bryan Hansen; Marinieve Montero; Olivia Steele-Mortimer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

Review 3.  Breaking through the acid barrier: an orchestrated response to proton stress by enteric bacteria.

Authors:  J P Audia; C C Webb; J W Foster
Journal:  Int J Med Microbiol       Date:  2001-05       Impact factor: 3.473

Review 4.  From bench to bedside: stealth of enteroinvasive pathogens.

Authors:  Renée M Tsolis; Glenn M Young; Jay V Solnick; Andreas J Bäumler
Journal:  Nat Rev Microbiol       Date:  2008-10-28       Impact factor: 60.633

5.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

6.  Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Authors:  B D Kirkpatrick; Robin McKenzie; J Patrick O'Neill; Catherine J Larsson; A Louis Bourgeois; Janet Shimko; Matthew Bentley; Jill Makin; Steve Chatfield; Zoë Hindle; Christine Fidler; Brad E Robinson; Cassandra H Ventrone; Nivedita Bansal; Colleen M Carpenter; Deborah Kutzko; Sandra Hamlet; Casey LaPointe; David N Taylor
Journal:  Vaccine       Date:  2005-08-18       Impact factor: 3.641

7.  Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features.

Authors:  J Wain; V B Pham; V Ha; N M Nguyen; S D To; A L Walsh; C M Parry; R P Hasserjian; V A HoHo; T H Tran; J Farrar; N J White; N P Day
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

8.  The Salmonella enterica serotype Typhi Vi capsular antigen is expressed after the bacterium enters the ileal mucosa.

Authors:  Quynh T Tran; Gabriel Gomez; Sangeeta Khare; Sara D Lawhon; Manuela Raffatellu; Andreas J Bäumler; Dharani Ajithdoss; Soma Dhavala; L Garry Adams
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

9.  Invasive Salmonella Typhimurium ST313 with naturally attenuated flagellin elicits reduced inflammation and replicates within macrophages.

Authors:  Girish Ramachandran; Darren J Perkins; Patrick J Schmidlein; Mohan E Tulapurkar; Sharon M Tennant
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

10.  An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution.

Authors:  Claire S Waddington; Thomas C Darton; Claire Jones; Kathryn Haworth; Anna Peters; Tessa John; Ben A V Thompson; Simon A Kerridge; Robert A Kingsley; Liqing Zhou; Kathryn E Holt; Ly-Mee Yu; Stephen Lockhart; Jeremy J Farrar; Marcelo B Sztein; Gordon Dougan; Brian Angus; Myron M Levine; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2014-02-10       Impact factor: 9.079

View more
  18 in total

1.  Protective efficacy of a Salmonella Typhimurium ghost vaccine candidate constructed with a recombinant lysozyme-PMAP36 fusion protein in a murine model.

Authors:  Ja Young Moon; So Young Kim; Won Kyong Kim; Zhili Rao; Jung Hee Park; Ji Young Mun; Boram Kim; Hyo Sun Choi; Jin Hur
Journal:  Can J Vet Res       Date:  2017-10       Impact factor: 1.310

Review 2.  Vaccination against Salmonella Infection: the Mucosal Way.

Authors:  Rémi Gayet; Gilles Bioley; Nicolas Rochereau; Stéphane Paul; Blaise Corthésy
Journal:  Microbiol Mol Biol Rev       Date:  2017-06-14       Impact factor: 11.056

Review 3.  Mucosal Vaccination: A Promising Alternative Against Flaviviruses.

Authors:  Rosendo Luria-Pérez; Luis A Sánchez-Vargas; Paola Muñoz-López; Gabriela Mellado-Sánchez
Journal:  Front Cell Infect Microbiol       Date:  2022-06-15       Impact factor: 6.073

4.  Differential functional patterns of memory CD4+ and CD8+ T-cells from volunteers immunized with Ty21a typhoid vaccine observed using a recombinant Escherichia coli system expressing S. Typhi proteins.

Authors:  Rosângela Salerno-Gonçalves; Hervé Tettelin; David Luo; Qin Guo; Matthew T Ardito; William D Martin; Anne S De Groot; Marcelo B Sztein
Journal:  Vaccine       Date:  2019-10-16       Impact factor: 3.641

5.  Immunogenicity and protection efficacy of enhanced fitness recombinant Salmonella Typhi monovalent and bivalent vaccine strains against acute toxoplasmosis.

Authors:  Fei-Kean Loh; Sheila Nathan; Sek-Chuen Chow; Chee-Mun Fang
Journal:  Pathog Glob Health       Date:  2021-02-01       Impact factor: 2.894

6.  Diversity of Salmonella Typhi-responsive CD4 and CD8 T cells before and after Ty21a typhoid vaccination in children and adults.

Authors:  Mark E Rudolph; Monica A McArthur; Laurence S Magder; Robin S Barnes; Wilbur H Chen; Marcelo B Sztein
Journal:  Int Immunol       Date:  2019-04-26       Impact factor: 5.071

7.  Bi-valent polysaccharides of Vi capsular and O9 O-antigen in attenuated Salmonella Typhimurium induce strong immune responses against these two antigens.

Authors:  Pei Li; Qing Liu; Hongyan Luo; Kang Liang; Yue Han; Kenneth L Roland; Roy Curtiss; Qingke Kong
Journal:  NPJ Vaccines       Date:  2018-01-09       Impact factor: 7.344

8.  Salmonella Typhi Colonization Provokes Extensive Transcriptional Changes Aimed at Evading Host Mucosal Immune Defense During Early Infection of Human Intestinal Tissue.

Authors:  K P Nickerson; S Senger; Y Zhang; R Lima; S Patel; L Ingano; W A Flavahan; D K V Kumar; C M Fraser; C S Faherty; M B Sztein; M Fiorentino; A Fasano
Journal:  EBioMedicine       Date:  2018-04-12       Impact factor: 8.143

9.  Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge.

Authors:  Kaitlin Winter; Li Xing; Audrey Kassardjian; Brian J Ward
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

10.  Impact of the Lipopolysaccharide Chemotype of Salmonella Enterica Serovar Typhimurium on Virulence in Gnotobiotic Piglets.

Authors:  Alla Splichalova; Zdislava Splichalova; Daniela Karasova; Ivan Rychlik; Paolo Trevisi; Marek Sinkora; Igor Splichal
Journal:  Toxins (Basel)       Date:  2019-09-13       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.